Department University Hospital General Thoracic Surgery, Clinical Departments Position
|Article types||journal article|
|Peer review||Peer reviewed|
|Title||Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer.|
|Journal||Formal name：Annals of translational medicine|
Abbreviation：Ann Transl Med
|Domestic / Foregin||Foregin|
|Volume, Issue, Page||6(20),401-401頁|
|Author and coauthor||Chikaishi Y1, Kanayama M1, Taira A1, Nabe Y1, Shinohara S1, Kuwata T1, Takenaka M1, Oka S1, Hirai A1, Kuroda K1, Imanishi N1, Ichiki Y1, Tanaka F1.|
The standard therapy for brain metastasis (BM) in non-small cell lung cancer (NSCLC) is radiation therapy (RT), although it is associated with complications such as leukoencephalopathy. In the current report, we retrospectively review data from eight patients who had NSCLC and harbored epidermal growth factor receptor (EGFR) mutations, and who were received erlotinib plus bevacizumab (E+B) as first-line therapy for BM.
Patients were given E+B as first therapy for BM until August 2017 at our institution. Patients receiving local therapy for BM, such as surgery or radiotherapy, were excluded. Patients were administered erlotinib orally (once daily at 150 mg/body) plus bevacizumab by intravenous infusion (15 mg/kg on day 1 of a 21- or 28-day cycle).
Eight NSCLC patients who were diagnosed with BM received E+B, including 2 men and 6 women with a median age of 65 years (range, 46-84 years). Four patients had an L858R EGFR mutation, while the other four had an exon 19 deletion. Seven patients had a partial response to E+B treatment, and one had a complete response. The 2-year survival rate was 62.5%. Three patients who were pre-treated with gefitinib had an E+B treatment duration of less than 1 year. At the time of this analysis, four patients had BM-related neurologic symptoms and multiple BMs, and were still receiving E+B with no evidence of treatment failure after more than 1 year.